BioSpace News Archive

Brii Biosciences Limited today announced that Brii Biosciences has been included as a constituent stock of the Hang Seng Composite Index.

Caris Life Sciences announced today the appointment of Lloyd B. Minor , M.D. to the Caris Board of Directors, effective immediately.

Vertex Pharmaceuticals Incorporated announced that the Spanish government has approved terms for the national reimbursement of KAFTRIO® in a combination regimen with ivacaftor for the treatment of cystic fibrosis for eligible patients.

OraSure Technologies, Inc., a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, announced that Dr. Stephen S. Tang, President and CEO, will participate in a virtual fireside chat at the Stephens Annual Investment Conference on November 29, 2021 at 12:00 pm ET.

Algernon Pharmaceuticals Inc. is pleased to announce that it has received positive feedback at a scientific advice meeting from the United Kingdom Medicines and Healthcare Products Regulatory Agency (“UK MHRA”).

Microbot Medical Inc. (Nasdaq: MBOT), announced that the United States Patent and Trade Office (USPTO) has issued a Notice of Allowance for a second patent application covering the Company’s LIBERTY ® Robotic System.

Evofem Biosciences, Inc., today announced that Chief Executive Officer Saundra Pelletier will participate in a fireside chat and host one-on-one meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held from November 29 – December 2, 2021.

Castle Biosciences, Inc. today announced the publication of a study of patients with stage I-III cutaneous melanoma.

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review of the New Drug Application (NDA) for mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to April 28, 2022.

Voyager Therapeutics, Inc. today will present preclinical data demonstrating that IV dosing of a proprietary AAV vector identified by the TRACER™️ screening technology, encoding an anti-HER2 antibody payload, prevented tumor growth in models of HER2+ brain metastases.